Praxis Precision Medicines, Inc.
vormatrigine
focal onset seizures and generalized epilepsy
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for vormatrigine in focal onset seizures and generalized epilepsy are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The full dataset from the RADIANT Phase 2 study were presented at the 2025 American Epilepsy Society Annual Meeting,”